Journey Medical Achieves Milestone Year with $14.7 Million in Net Sales from Newly Launched EMROSI Treatment
On March 25, 2026, Journey Medical's leadership team, including Co-founder and President Claude Maraoui, Chief Financial Officer Joseph Benesch, and Chief Operating Officer and General Counsel Ramsey Alloush, presented the company's Full Year 2025 Financial Results and Corporate Update during a conference call.
During the call, Claude Maraoui highlighted that 2025 was a milestone year for Journey Medical as they successfully launched EMROSI, their internally developed best-in-class oral treatment for inflammatory lesions of rosacea. According to Maraoui, EMROSI achieved $14.7 million in net sales during its three quarters of commercial availability, starting from late March 2025.
Notably, Journey Medical's full year 2025 performance showed a total net product revenue growth of 11%, with an improvement in gross margin by nearly 3.5 percentage points compared to the 2024 period. Despite facing pressure on their Accutane franchise and other legacy products due to generic competition, the company managed to maintain positive adjusted EBITDA and EBITDA for Q4 2025.
"I am pleased to report that during the three quarters of 2025 in which EMROSI was commercially available, the product achieved $14.7 million in net sales," said Maraoui. "Our business has made solid financial progress despite pressure on our Accutane franchise and other legacy products due to generic competition."
Journey Medical's strong prescription volume for EMROSI is another key highlight from 2025. According to the company, total EMROSI prescriptions were approximately 53,000 since promotion began in April of last year, with a nearly 50% sequential growth in Q4 compared to Q3. This positive trend continues into Q1 of this year.
The sales organization's continued promotional efforts have contributed to EMROSI's rising popularity among physicians and patients alike. Physician feedback has been very positive, while the high refill rate for EMROSI demonstrates that patients are pleased with the treatment results.
"Our sales organization continues to promote the superior efficacy of EMROSI compared to the only other branded oral rosacea treatment, ORACEA," Maraoui explained. "Notably, the extremely positive head-to-head results against ORACEA and placebo in EMROSI's phase III clinical trials are playing out in the real world."
Going forward, Journey Medical is confident about their ability to execute on their business plan with a solid cash position of approximately $24 million. The company expects continued sales growth and additional leverage from their established commercial sales organization, aiming for adjusted EBITDA positive in 2026 and beyond.
